UNSPSC 51432405: Captopril disulfide

This classification denotes an ace inhibitor with the molecular formula C18H28N2O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y21D2C2453, chemically known as l-proline, 1,1'-(dithiobis(2-methyl-1-oxo-3,1-propanediyl))bis-, (s-(r*,r*))-, but more generally known as captopril disulfide, which bears US NIH Compound Identifier 163066. European Medicines Agency schedules captopril disulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06081MIG.

Most nations, for tariff purposes, schedule captopril disulfide under HS 29339990. SMILES: C[C@H](CSSC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O)C(=O)N2CCC[C@H]2C(=O)O.

UNSPSC 51432405 Captopril disulfide, a Commodity code, encompasses pharmaceutical products supplied to state and local healthcare and emergency-response agencies. State and local governments procure pharmaceutical medications through this code for use by fire departments, emergency medical services, health commissions, and other government health providers. The issuing bodies soliciting under this code include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing consortia. Tampa Fire Rescue's Advanced Life Support Medications procurement and the Texas Health and Human Services Commission's Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions initiative both draw under this commodity classification.

Recent activity spans Florida, Texas, and the multistate purchasing ecosystem covering Oregon and additional participating jurisdictions. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem with a response deadline of April 8, 2026 and estimated contract value of $40,000; the procurement carried a 5 percent Small Local Business Enterprise bid discount not to exceed $10,000 and required one-year initial term with two optional one-year renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP for Generic Multi Source Pharmaceuticals and OTC Products on January 20, 2026, with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers with products available by May 15, 2026, and effective contract date of July 1, 2026; evaluation weighted price competitiveness at 75 percent with fixed pricing, EDI capability, and compliance with administrative requirements comprising the remainder. The Texas HHS Commission issued an RFI on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs and vendor direct-contracting capacity prior to formal procurement.